{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:47:29Z","timestamp":1785754049339,"version":"3.56.0"},"reference-count":132,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Disability and Ageing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2030765"],"award-info":[{"award-number":["2030765"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2025894"],"award-info":[{"award-number":["2025894"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There have been concerted research efforts internationally to examine the health effects of higher delta\u20109\u2010tetrahydrocannabinol (THC) concentration cannabis products and to design policies to reduce potential negative health effects of their use. This study identifies international policy approaches for regulating higher THC products relevant to the Australian medicinal cannabis program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An environmental scan of international literature and policy as part of a broader study commissioned to inform Australian policy. Methods were prospectively registered with the Open Science Framework:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/doi.org\/10.17605\/OSF.IO\/HNFUT\">10.17605\/OSF.IO\/HNFUT<\/jats:ext-link>\n                      . Peer\u2010reviewed and grey literature on international policy approaches were identified through searches for \u2018high potency THC\u2019 and \u2018policy\u2019. The literature was then narratively synthesised.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 76 publications and other sources that described policy approaches recommended or implemented in five jurisdictions: Canada; Germany; the Netherlands; the United States; and Uruguay. Approaches included setting a threshold for cannabis flower THC concentration at or below the biological THC limit of 30%\u201335% found in the plant and a risk\u2010tiered model for highly concentrated THC dosage forms. THC limits per dose and per package have been applied to edible products. Additional approaches included quantity limits, packaging and labelling requirements, pharmacovigilance, and education.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and Conclusions<\/jats:title>\n                    <jats:p>Policy approaches for higher THC concentration cannabis products could be adapted to the Australian regulatory environment to reduce potentially harmful THC exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dar.70203","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:31:09Z","timestamp":1784111469000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["International Policy Approaches for Higher\n                    <scp>THC<\/scp>\n                    Cannabis Products: Are They Applicable to the Australian Medicinal Cannabis Framework?"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-7497","authenticated-orcid":false,"given":"Myfanwy","family":"Graham","sequence":"first","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School, Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dereje","family":"Assefa","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School, Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Carter","sequence":"additional","affiliation":[{"name":"School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University  Melbourne Australia"},{"name":"Monash Bioethics Centre, School of Philosophy, History and International Studies, Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School, Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"National Academies of Sciences Engineering and Medicine \u201cCannabis Policy Impacts Public Health and Health Equity \u201d2024 https:\/\/nap.nationalacademies.org\/catalog\/27766\/cannabis\u2010policy\u2010impacts\u2010public\u2010health\u2010and\u2010health\u2010equity."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-03819"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2023.307414"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240269"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16182"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.70145"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.921493"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14525"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15253"},{"key":"e_1_2_12_11_1","unstructured":"Therapeutic Goods Administration \u201cMedicinal Cannabis Products by Active Ingredients \u201d2025 https:\/\/www.tga.gov.au\/products\/unapproved\u2010therapeutic\u2010goods\/medicinal\u2010cannabis\u2010hub\/medicinal\u2010cannabis\u2010products\u2010active\u2010ingredients."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104974"},{"key":"e_1_2_12_13_1","unstructured":"Therapeutic Goods Administration \u201cConsultation Paper: Reviewing the Safety and Regulatory Oversight of Unapproved Medicinal Cannabis Products \u201d2025 https:\/\/consultations.tga.gov.au\/medicines\u2010regulation\u2010division\/test\u2010soms\/user_uploads\/final\u2010\u2010\u2010consultation\u2010paper\u2010\u2010\u2010medicinal\u2010cannabis\u2010review\u2010\u2010\u2010august\u20102025.pdf."},{"key":"e_1_2_12_14_1","unstructured":"Therapeutic Goods Administration \u201cMedicinal Cannabis Vaping Devices That are Approved in Australia \u201d2025 https:\/\/www.tga.gov.au\/resources\/explore\u2010topic\/medicinal\u2010cannabis\u2010hub\/medicinal\u2010cannabis\u2010vaping\u2010devices\u2010are\u2010approved\u2010australia."},{"key":"e_1_2_12_15_1","unstructured":"Therapeutic Goods Administration \u201cGuidance for the Use of Medicinal Cannabis in Australia: Overview \u201d2025 https:\/\/www.tga.gov.au\/resources\/explore\u2010topic\/medicinal\u2010cannabis\u2010hub\/medicinal\u2010cannabis\u2010guidance\u2010documents\/guidance\u2010use\u2010medicinal\u2010cannabis\u2010australia\u2010overview."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674261445267"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104210"},{"key":"e_1_2_12_18_1","unstructured":"AHPRA \u201cGuidance on Medicinal Cannabis Prescribing Targets Unsafe Practice \u201d2025 https:\/\/www.ahpra.gov.au\/News\/2025\u201007\u201009\u2010Medicinal\u2010cannabis\u2010guidance.aspx."},{"key":"e_1_2_12_19_1","unstructured":"Therapeutic Goods Administration \u201cSAS B Application Dashboard \u201d2025 https:\/\/www.tga.gov.au\/products\/unapproved\u2010therapeutic\u2010goods\/medicinal\u2010cannabis\u2010hub\/medicinal\u2010cannabis\u2010access\u2010pathways\u2010and\u2010usage\u2010data\/medicinal\u2010cannabis\u2010special\u2010access\u2010scheme\u2010data."},{"key":"e_1_2_12_20_1","unstructured":"K.SatoandK.O'Toole \u201cTelehealth Medicinal Cannabis Providers are Under\u2010Regulated Medical Bodies AMA and RACGP \u201d2024 https:\/\/www.abc.net.au\/news\/2024\u201004\u201003\/telehealth\u2010medicinal\u2010cannabis\u2010providers\u2010ama\u2010racgp\u2010warnings\/103658706."},{"key":"e_1_2_12_21_1","unstructured":"Australian Medical Association \u201cRobust Regulation Needed to Tackle Medicinal Cannabis Prescribing \u201dhttps:\/\/www.ama.com.au\/media\/robust\u2010regulation\u2010needed\u2010tackle\u2010medicinal\u2010cannabis\u2010prescribing."},{"key":"e_1_2_12_22_1","unstructured":"Australian Medical Association \u201cPresident's Update: AMA and Guild Call for Urgent Action on Medicinal Cannabis \u201d2025 https:\/\/www.ama.com.au\/ama\u2010rounds\/17\u2010october\u20102025\/articles\/presidents\u2010update\u2010ama\u2010and\u2010guild\u2010call\u2010urgent\u2010action\u2010medicinal."},{"key":"e_1_2_12_23_1","unstructured":"AMA Queensland RACGP Pharmacy Guild and RANZCP \u201cMedicinal Cannabis National Approach \u201d2025 https:\/\/www.ama.com.au\/sites\/default\/files\/2025\u201002\/250131%20Joint%20AMAQ%20RANZCP%20RACGP%20Guild%20letter%20to%20Mins%20Butler%20and%20Nicholls%20re%20medicinal%20cannabis_Redacted.pdf."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/10398562231222818"},{"key":"e_1_2_12_25_1","article-title":"A Decade of Cannabis\u2010Related Hospital Admissions in Victoria, Australia","author":"Graham M.","year":"2026","journal-title":"Under Journal Consideration"},{"key":"e_1_2_12_26_1","unstructured":"Therapeutic Goods Administration \u201cConsultation: Reviewing the Safety and Regulatory Oversight of Unapproved Medicinal Cannabis Products \u201d Feedback updated 21 Apr 2026 2026 https:\/\/consultations.tga.gov.au\/medicines\u2010regulation\u2010division\/test\u2010soms\/."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.37464\/2024.413.816"},{"key":"e_1_2_12_28_1","unstructured":"Government of Canada \u201cCannabis Legalization and Regulation \u201d2021 https:\/\/www.justice.gc.ca\/eng\/cj\u2010jp\/cannabis\/."},{"key":"e_1_2_12_29_1","unstructured":"Government of Canada \u201cGuide on Composition Requirements for Cannabis Products \u201d2025 https:\/\/www.canada.ca\/en\/services\/health\/publications\/drugs\u2010health\u2010products\/composition\u2010requirements\u2010cannabis\u2010products.html."},{"key":"e_1_2_12_30_1","unstructured":"Ministry of Health Welfare and Sport \u201cOffice of Medicinal Cannabis \u201d2025 https:\/\/english.cannabisbureau.nl."},{"key":"e_1_2_12_31_1","unstructured":"Government of the Netherlands \u201cToleration Policy Regarding Soft Drugs and Coffee Shops \u201d2025 https:\/\/www.government.nl\/topics\/drugs\/toleration\u2010policy\u2010regarding\u2010soft\u2010drugs\u2010and\u2010coffee\u2010shops."},{"key":"e_1_2_12_32_1","unstructured":"Government of Canada \u201cAuthorized Cannabis Retailers in the Provinces and Territories \u201d2022 https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010medication\/cannabis\/laws\u2010regulations\/provinces\u2010territories.html."},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100929"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2024.112352"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01369-8"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.70117"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.01.017"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-023-00189-6"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2261-2269"},{"key":"e_1_2_12_40_1","unstructured":"California Department of Public Health \u201cReport and Recommendations of the High Potency Cannabis Think Tank to the State of California \u201d2024 https:\/\/www.gettingitrightfromthestart.org\/wp\u2010content\/uploads\/2024\/10\/California\u2010High\u2010Potency\u2010Cannabis\u2010Think\u2010Tank\u2010Report\u201010\u201030\u201024.pdf."},{"key":"e_1_2_12_41_1","unstructured":"R. L.Pacula S. C.Pessar J.Zhu A.Kritikos andR.Smart \u201cFederal Regulation of Cannabis for Public Health in the United States \u201d2022 https:\/\/schaeffer.usc.edu\/wp\u2010content\/uploads\/2024\/10\/USC\u2010Schaeffer\u2010Center\u2010white\u2010paper_Federal\u2010Regulation\u2010of\u2010Cannabis\u2010for\u2010Public\u2010Health\u2010in\u2010the\u2010United\u2010States.pdf."},{"key":"e_1_2_12_42_1","unstructured":"State of Vermont Cannabis Control Board \u201cFrequently Asked Questions \u201d2024http:\/\/ccb.vermont.gov\/FAQ."},{"key":"e_1_2_12_43_1","unstructured":"National Conference of State Legislatures \u201cOverview of High Potency Cannabis and THC Concentrate Product Legislative Enactment Through 2023\u20132024 \u201d2024."},{"key":"e_1_2_12_44_1","unstructured":"Montana Department of Revenue \u201cCannabis Control Division Montana. Purchasing Power \u201d2024 https:\/\/mtrevenue.gov\/122004\u20102\/."},{"key":"e_1_2_12_45_1","unstructured":"Government of Canada \u201cCannabis for Medical Purposes under the Cannabis Act: Information and Improvements \u201d2024 https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010medication\/cannabis\/medical\u2010use\u2010cannabis.html."},{"issue":"2","key":"e_1_2_12_46_1","first-page":"25","article-title":"Market Revenues and Economic Opportunities in the Legal Cannabis Market in Uruguay","volume":"7","author":"Rychert M.","year":"2025","journal-title":"Journal of Industrial Engineering and Management"},{"key":"e_1_2_12_47_1","unstructured":"Office of Medicinal Cannabis The Netherlands \u201cTypes of Medicinal Cannabis \u201d2024 https:\/\/english.cannabisbureau.nl\/medicinal\u2010cannabis\/types\u2010of\u2010medicinal\u2010cannabis."},{"key":"e_1_2_12_48_1","unstructured":"Cannabis Regulators Association \u201cBest Practices and Guidance for Regulating Cannabinoids for Safety \u201d2024 https:\/\/static1.squarespace.com\/static\/5f7e577e23ad7c718c269776\/t\/663c038804aa7e058ab49a72\/1715209097353\/Best+Practices+in+Minimum+Requirements+for+Regulating+Cannabinoids\u2010FINAL+5.5.24.pdf."},{"key":"e_1_2_12_49_1","unstructured":"Government of Canada \u201cGuide on Composition Requirements for Cannabis Products \u201d2025 https:\/\/www.canada.ca\/en\/services\/health\/publications\/drugs\u2010health\u2010products\/composition\u2010requirements\u2010cannabis\u2010products.html."},{"key":"e_1_2_12_50_1","unstructured":"The Network for Public Health Law \u201cTHC Limits for Adult\u2010Use Cannabis Products \u201d2022 https:\/\/www.networkforphl.org\/wp\u2010content\/uploads\/2022\/11\/THC\u2010limits\u2010for\u2010Adult\u2010Use\u2010Cannabis\u2010Products.pdf."},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.105038"},{"key":"e_1_2_12_52_1","unstructured":"Gouvernement du Qu\u00e9bec \u201cThe Cannabis Regulation Act \u201d2026 https:\/\/www.quebec.ca\/en\/health\/advice\u2010and\u2010prevention\/alcohol\u2010drugs\u2010gambling\/recognizing\u2010drugs\u2010and\u2010their\u2010effects\/cannabis\/regulating\u2010cannabis\u2010in\u2010quebec\/cannabis\u2010regulation\u2010act."},{"key":"e_1_2_12_53_1","unstructured":"Vermont Legislature \u201cBill Status S.54 (Act 164). An Act Relating to the Regulation of Cannabis \u201d2020 https:\/\/legislature.vermont.gov\/bill\/status\/2020\/S.54."},{"key":"e_1_2_12_54_1","unstructured":"Connecticut Government \u201cAdult\u2010Use Cannabis in Connecticut. What's in Effect Now?\u201d2024 https:\/\/portal.ct.gov\/cannabis\/knowledge\u2010base\/articles\/what\u2010is\u2010in\u2010effect\u2010now?language=en_US."},{"key":"e_1_2_12_55_1","unstructured":"Mississippi State Department of Health \u201cPart 22\u2013Medical Cannabis Program \u201d|https:\/\/www.mmcp.ms.gov\/sites\/default\/files\/Documents\/MMCP%20Regs%20adopted%2010.23%20by%20Board.%20Final%20vs.%20Black%20lined%20only%201.12.24.pdf."},{"key":"e_1_2_12_56_1","unstructured":"Mississippi Legislature \u201cHouse Bill 1158 \u201d2023 https:\/\/billstatus.ls.state.ms.us\/documents\/2023\/html\/HB\/1100\u20101199\/HB1158PS.htm."},{"key":"e_1_2_12_57_1","unstructured":"Montana Code Annotated \u201dTitle 16. Alcohol Tobacco and Marijuana. Chapter\u00a012. Marijuana Regulation and Taxation \u201d2023 https:\/\/archive.legmt.gov\/bills\/mca\/title_0160\/chapter_0120\/part_0010\/section_0010\/0160\u20100120\u20100010\u20100010.html."},{"key":"e_1_2_12_58_1","unstructured":"Federal Ministry of Health \u201cFrequently Asked Questions on the Cannabis Act \u201d2025 https:\/\/www.bundesgesundheitsministerium.de\/en\/themen\/cannabis\/faq\u2010cannabis\u2010act.html."},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1196160"},{"key":"e_1_2_12_60_1","unstructured":"The Senate and House of Representatives of the Oriental Republic of Uruguay \u201cLaw No 19.172. Marijuana and its Derivatives. Control and Regulation of the Status of Importation Production Purchase Storage Marketing and Distribution\u201d."},{"key":"e_1_2_12_61_1","unstructured":"Trimbos Institute \u201cCannabis \u201d2026 https:\/\/www.nationaledrugmonitor.nl\/cannabis\u2010laatste\u2010feiten\u2010en\u2010trends\/."},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.26828\/cannabis\/2023.01.001"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2020.11.005"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.02.007"},{"key":"e_1_2_12_65_1","unstructured":"New York Office of Cannabis Management \u201cMedical Cannabis Program FAQs \u201d2025 https:\/\/cannabis.ny.gov\/medical\u2010cannabis\u2010program\u2010faqs."},{"key":"e_1_2_12_66_1","unstructured":"Colorado Research and Policy Project Team \u201cPolicy Approaches to High Concentration Cannabis and THC Concentrates \u201d2024 https:\/\/coloradosph.cuanschutz.edu\/docs\/librariesprovider151\/default\u2010document\u2010library\/policy\u2010approaches\u2010to\u2010high\u2010concentration\u2010cannabis\u2010and\u2010thc\u2010concentrates\u2010\u2010\u2010march\u201027\u20102024.pdf?sfvrsn=c96cc8bb_1."},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104718"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107633"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.3117"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-6247-2"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107843"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2207661"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-061374"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2023.2238121"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2016.0971"},{"key":"e_1_2_12_76_1","article-title":"The Non\u2010Medical Cannabis Regime in Qu\u00e9bec: A Public Health Analysis","author":"Gagnon F.","year":"2021","journal-title":"Institut National De Sant\u00e9 Publique Du Qu\u00e9bec"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2025.2479152"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104453"},{"key":"e_1_2_12_79_1","unstructured":"HealthCanada \u201cPolicy Statement on Cannabis Act Prohibitions Referring to Appeal to Young Persons \u201d2019 https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/cannabis\u2010regulations\u2010licensed\u2010producers\/prohibitions\u2010referring\u2010appeal\u2010young\u2010persons.html."},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4911"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70047"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70046"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2023.103828"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-025-00310-x"},{"key":"e_1_2_12_85_1","unstructured":"Colorado School of Public Health \u201cThe Tea on THC \u201d2024 https:\/\/teaonthc.org\/."},{"key":"e_1_2_12_86_1","unstructured":"Health Canada Experiences \u201cAll About Cannabis \u201d2026 https:\/\/healthcanadaexperiences.ca\/programs\/all\u2010about\u2010cannabis\/."},{"key":"e_1_2_12_87_1","unstructured":"Public Health Agency of Canada \u201cCanada's Lower\u2010Risk Cannabis Use Guidelines \u201d2019 https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010medication\/cannabis\/resources\/lower\u2010risk\u2010cannabis\u2010use\u2010guidelines.html."},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0061"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1177\/17151635211041041"},{"issue":"4","key":"e_1_2_12_90_1","first-page":"2088","article-title":"Mandatory Pharmacist\u2010Led Education Session for Patients Seeking Medical Cannabis","volume":"18","author":"Parihar V.","year":"2020","journal-title":"Canadian Pharmacists Journal"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00748"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102573"},{"key":"e_1_2_12_93_1","unstructured":"HealthCanada \u201cCannabis Health Warning Messages \u201d2025 https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010medication\/cannabis\/laws\u2010regulations\/regulations\u2010support\u2010cannabis\u2010act\/health\u2010warning\u2010messages.html."},{"key":"e_1_2_12_94_1","unstructured":"HealthCanada \u201cCannabis Health Warning Messages: Feedback From Canadians on Testing New Messages \u201d2025 https:\/\/publications.gc.ca\/collections\/collection_2025\/sc\u2010hc\/H14\u2010652\u20102025\u2010eng.pdf."},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S135252"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15108"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.630602"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12508"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.70118"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwae421"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13695"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2024.307789"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2152"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-022-00124-1"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.07.004"},{"key":"e_1_2_12_106_1","unstructured":"Government of Western Australia Department of Health \u201cMedicinal Cannabis Products (S4 and S8) \u201d2026 https:\/\/www.health.wa.gov.au\/Articles\/J_M\/monitored\u2010medicines\/medicinal\u2010cannabis\u2010products."},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104457"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5425"},{"key":"e_1_2_12_109_1","unstructured":"Therapeutic Goods Administration \u201cClarification of Requirements to Access Unapproved Medicinal Cannabis Medicines for Paediatric Patients \u201d2025 https:\/\/www.tga.gov.au\/resources\/publication\/corporate\u2010reports\/clarification\u2010requirements\u2010access\u2010unapproved\u2010medicinal\u2010cannabis\u2010medicines\u2010paediatric\u2010patients."},{"key":"e_1_2_12_110_1","unstructured":"Therapeutic Goods Administration \u201cLabelling and Packaging \u201d2022 https:\/\/www.tga.gov.au\/products\/regulations\u2010all\u2010products\/labelling\u2010and\u2010packaging\/labelling\u2010and\u2010packaging."},{"key":"e_1_2_12_111_1","unstructured":"Therapeutic Goods Administration \u201cComplying With Quality Requirements for Medicinal Cannabis \u201d2024 https:\/\/www.tga.gov.au\/resources\/guidance\/complying\u2010quality\u2010requirements\u2010medicinal\u2010cannabis."},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.13.04076"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674241307158"},{"key":"e_1_2_12_114_1","unstructured":"Ausdoc \u201cTGA Audit Reveals Poor Quality Control for Medicinal Cannabis \u201d2020 https:\/\/www.ausdoc.com.au\/news\/tga\u2010audit\u2010reveals\u2010poor\u2010quality\u2010control\u2010medicinal\u2010cannabis\/."},{"key":"e_1_2_12_115_1","unstructured":"Therapeutic Goods Administration \u201cTesting of Medicinal Cannabis Products Being Supplied via SAS in Australia\u2014Content of Cannabinoids and Presence of Delta\u20108\u2010THC \u201d2024 https:\/\/www.tga.gov.au\/resources\/publication\/tga\u2010laboratory\u2010testing\u2010reports\/testing\u2010medicinal\u2010cannabis\u2010products\u2010being\u2010supplied\u2010sas\u2010australia\u2010content\u2010cannabinoids\u2010and\u2010presence\u2010delta\u20108\u2010thc."},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50616"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085166"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4999"},{"key":"e_1_2_12_119_1","unstructured":"Government of Canada \u201cCannabis Adverse Reaction Reporting for Licence Holders: Reporting Procedures \u201d2025 https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/publications\/drugs\u2010health\u2010products\/cannabis\u2010adverse\u2010reaction\u2010reporting\u2010licence\u2010holders\/reporting\u2010procedures.html."},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.03.007"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103381"},{"key":"e_1_2_12_122_1","unstructured":"Royal Australian & New Zealand College of Psychiatrists \u201cClinical Memorandum on the Therapeutic Use of Medicinal Cannabis Products \u201d2024 https:\/\/www.ranzcp.org\/getmedia\/233218fd\u2010068d\u20104846\u2010875e\u20103bf319bb5d0a\/cm\u2010therapeutic\u2010use\u2010of\u2010medicinal\u2010cannabis\u2010products.pdf."},{"key":"e_1_2_12_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104270"},{"key":"e_1_2_12_124_1","unstructured":"Therapeutic Goods Administration \u201cThe Black Triangle Scheme \u201d2024 https:\/\/www.tga.gov.au\/safety\/adverse\u2010events\/medicine\u2010adverse\u2010events\/obligations\u2010report\u2010adverse\u2010events\u2010medicines\u2010and\u2010biologicals\/black\u2010triangle\u2010scheme."},{"key":"e_1_2_12_125_1","unstructured":"Therapeutic Goods Administration \u201cUsing a Boxed Warning in Product Information (PI) or Consumer Medicine Information (CMI) \u201d(2024) https:\/\/www.tga.gov.au\/resources\/guidance\/using\u2010boxed\u2010warning\u2010product\u2010information\u2010pi\u2010or\u2010consumer\u2010medicine\u2010information\u2010cmi."},{"key":"e_1_2_12_126_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-032816-045128"},{"key":"e_1_2_12_127_1","article-title":"What Can the Regulation of Cannabis Learn From Alcohol and Tobacco?","author":"Ritter A.","year":"2024","journal-title":"DPMP Evidence Hub for the NSW Drug Summit 2024, Social Policy Research Centre, UNSW"},{"key":"e_1_2_12_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103744"},{"key":"e_1_2_12_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18105174"},{"key":"e_1_2_12_130_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRA.0000000000000907"},{"key":"e_1_2_12_131_1","first-page":"103985622514060","article-title":"Stimulant and Medicinal Cannabis Prescribing in Patients Referred to an Early Psychosis Service in Queensland: A Brief Report","volume":"13","author":"McArdle P.","year":"2025","journal-title":"Australasian Psychiatry"},{"key":"e_1_2_12_132_1","unstructured":"Advisory Council on the Misuse of Drugs \u201cCannabis\u2010Based Products for Medicinal Use \u201d2025 https:\/\/www.gov.uk\/government\/calls\u2010for\u2010evidence\/cannabis\u2010based\u2010products\u2010for\u2010medicinal\u2010use."},{"key":"e_1_2_12_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11469\u2010025\u201001574\u20103"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.70203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dar.70203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.70203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:18:26Z","timestamp":1785752306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.70203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":132,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/dar.70203"],"URL":"https:\/\/doi.org\/10.1111\/dar.70203","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70203"}}